Oncolytics Biotech Inc T.ONC

Simply Wall Street determines ONCY fair value at $157 p/s

[Noteable]

on a NPV of $ 8 billion US for ONCY in the mBC indication by itself. Their analysis did not take into consideration either the pancreatic or the colorectal cancer indications. Nor did they take into consideration pelareorep's application in combination with CAR-T, bispecifics or small molecules such as PARP and CDK4/6 inhibitors in multiple other cancer indications.

https://simplywall.st/stocks/ca/pharmaceuticals-biotech/tsx-onc/oncolytics-biotech-shares

[fox7mf]

Making an Immunomedics type valuation not completely out of the question;)

[Noteable]

Yes .. making an Immunomedics type buy-out valuation entirely a possibility.

[fox7mf]

Oncy's value should continue to increase after the Vile & Loghmani Car-T presentation on Wednesday. We'll see if we get any official NR from Onc on it or if the blackout on news will continue beyond 75 days.

[Noteable]

At no time in the past has any stock analysis company like SWS determined that ONCY's fair value was worth $157 per share on a NPV of $ 8 billion US for ONCY in the mBC indication by itself. Now that ONCY has potentially 2 Phase 3 cliical trials in breast and pancreatic cancer followed by pelareorep's application in combination with CAR-T, bispecifics or small molecules such as

[Noteable]

And at no time in the past 24 years has ONCY been ready to move towards a registration study with pelareorep in combination with a biomarker in multiple cancer indications. Over this time ONCY has been able to demonstrate that pelareorep induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and

[Noteable]

And because Matt Coffey hired "new" doctoral level scientists, who have worked to bring ONCY through the breast, pancreatic, colorectal and the AWARE-1 clinical studies in partnership with Pfizer/Merck KGaA Serono and Roche ONCY is a different company than some seem to remember.  As a consequence independent stock analysis companies like SWS determine that ONCY's fair value is

[Noteable]

on a NPV of $ 8 billion US for ONCY in the mBC indication by itself. Their analysis did not take into consideration either the pancreatic or the colorectal cancer indications. Nor did they take into consideration pelareorep's application in combination with CAR-T, bispecifics or small molecules such as PARP and CDK4/6 inhibitors in multiple other cancer indications. So USD 12-15 Bln is not

[Noteable]

And focus on this fair value in the process ....

[Noteable]

See for yourself ... https://simplywall.st/stocks/ca/pharmaceuticals-biotech/tsx-onc/oncolytics-biotech-shares

[Noteable]

Maybe I should have said .. "Judge" for yourself.